Related references
Note: Only part of the references are listed.Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Evan T. Powers et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2009)
Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and Stability
Raquel L. Lieberman et al.
BIOCHEMISTRY (2009)
Lysosomal disorders: From storage to cellular damage
Andrea Ballabio et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2009)
Chaperone-Like Antibodies in Neurodegenerative Tauopathies: Implication for Immunotherapy
Eva Kontsekova et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2009)
The pharmacological chaperone 1-deoxygalactonojirimycin increases α-galactosidase A levels in Fabry patient cell lines
E. R. Benjamin et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2009)
Rational Design and Synthesis of Highly Potent Pharmacological Chaperones for Treatment of N370S Mutant Gaucher Disease
Guan-Nan Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Molecular interaction of imino sugars with human α-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease
Kanako Sugawara et al.
MOLECULAR GENETICS AND METABOLISM (2009)
The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts
Caterina Porto et al.
MOLECULAR THERAPY (2009)
Glycoengineered Acid alpha-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease
Yunxiang Zhu et al.
MOLECULAR THERAPY (2009)
Intrathecal Enzyme Replacement Therapy in a Patient With Mucopolysaccharidosis Type I and Symptomatic Spinal Cord Compression
Maria-Veronica Munoz-Rojas et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2008)
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase
Jin-Song Shen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Chemical and biological approaches synergize to ameliorate protein-folding diseases
Ting-Wei Mu et al.
CELL (2008)
Isofagomine Induced Stabilization of Glucocerebrosidase
Gregory J. Kornhaber et al.
CHEMBIOCHEM (2008)
Identification of Pharmacological Chaperones for Gaucher Disease and Characterization of Their Effects on β-Glucocerebrosidase by Hydrogen/Deuterium Exchange Mass Spectrometry
Michael B. Tropak et al.
CHEMBIOCHEM (2008)
Binding with parameters and thermodynamics of the interaction of imino sugars a recombinant human acid α-glucosidase (alglucosidase alfa):: Insight into the complex formation mechanism
Michiru Yoshimizu et al.
CLINICA CHIMICA ACTA (2008)
Optimization and Validation of Two Miniaturized Glucocerebrosidase Enzyme Assays for High Throughput Screening
Daniel J. Urban et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2008)
Conformational Changes and Aggregation of Expanded Polyglutamine Proteins as Therapeutic Targets of the Polyglutamine Diseases: Exposed beta-Sheet Hypothesis
Yoshitaka Nagai et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA
Stefan Worgall et al.
HUMAN GENE THERAPY (2008)
Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II
Gaelle Douillard-Guilloux et al.
HUMAN MOLECULAR GENETICS (2008)
In Vivo and in Vitro Examination of Stability of Primary Hyperoxaluria-associated Human Alanine: Glyoxylate Aminotransferase
Erin D. Hopper et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria
Angel L. Pey et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III
J. Cox-Brinkman et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
Lysosomal storage disease 2 - Pompe's disease
Ans T. van der Ploeg et al.
LANCET (2008)
Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis
Elena Elliot-Smith et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Targeting of the CNS in MPS-IH using a nonviral transferrin-α-L-iduronidase fusion gene product
Mark J. Osborn et al.
MOLECULAR THERAPY (2008)
Chemically modified β-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysacchariclosis VII
Jeffrey H. Grubb et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB
Elizabeth Ficko-Blean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Chemical and Biological Folding Contribute to Temperature-Sensitive ΔF508 CFTR Trafficking
Xiaodong Wang et al.
TRAFFIC (2008)
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis
Ting-Wei Mu et al.
PLOS BIOLOGY (2008)
Chemical chaperone therapy:: Clinical effect in murine GM1-gangliosidosis
Yoshiyuki Suzuki et al.
ANNALS OF NEUROLOGY (2007)
Pharmacologic chaperoning as a strategy to treat Gaucher disease
Zhanqian Yu et al.
FEBS JOURNAL (2007)
Hematopoietic cell therapy for metabolic disease
Paul J. Orchard et al.
JOURNAL OF PEDIATRICS (2007)
Active-site-specific chaperone therapy for Fabry disease
Jian-Qiang Fan et al.
FEBS JOURNAL (2007)
Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of NIPSIIIA
Ainslie L. K. Roberts et al.
MOLECULAR GENETICS AND METABOLISM (2007)
Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study
Marc C. Patterson et al.
LANCET NEUROLOGY (2007)
Three classes of gluclocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease
Wei Zheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis
Gustavo H. B. Maegawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Pharmacological enhancement of mutated α-glucosidase activity in fibroblasts from patients with Pompe disease
Giancarlo Parenti et al.
MOLECULAR THERAPY (2007)
Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease
Raquel L. Lieberman et al.
NATURE CHEMICAL BIOLOGY (2007)
Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II
Toshika Okumiya et al.
MOLECULAR GENETICS AND METABOLISM (2007)
The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat
A. Treiber et al.
XENOBIOTICA (2007)
Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease
Tokiko Fukuda et al.
MOLECULAR THERAPY (2006)
Lysosomal storage diseases: Natural history and ethical and economic aspects
Ernest Beutler
MOLECULAR GENETICS AND METABOLISM (2006)
Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses
Ewa Piotrowska et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2006)
Gene therapy for lysosomal storage diseases
Mark S. Sands et al.
MOLECULAR THERAPY (2006)
Limitations of enzyme replacement therapy: Current and future
J. E. Wraith
JOURNAL OF INHERITED METABOLIC DISEASE (2006)
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus
Virginie Bernier et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles
AR Sawkar et al.
CHEMISTRY & BIOLOGY (2005)
Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses
TD Butters et al.
GLYCOBIOLOGY (2005)
An open-label, noncomparative study of miglustat in type I Gaucher disease: Efficacy and tolerability over 24 months of treatment
GM Pastores et al.
CLINICAL THERAPEUTICS (2005)
Pharmacological enhancement of β-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients
MB Tropak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17
G Bonapace et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
U Andersson et al.
NEUROBIOLOGY OF DISEASE (2004)
The cell biology of lysosomal storage disorders
AH Futerman et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease
UH Schueler et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2004)
Chemical chaperone therapy for brain pathology in GM1-gangliosidosis
J Matsuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Quality control in the endoplasmic reticulum
L Ellgaard et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Brief report: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy.
A Frustaci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease
V Koprivica et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2000)
Share Paper
